ILUMYA
Google image searchProduct monograph
Active ingredient
tildrakizumab, 100 MG/ML
DIN: 02516098
Dosage form(s): SOLUTION
Route(s) of administration: SUBCUTANEOUS
Description: SINGLE-DOSE PREFILLED SYRINGE
Schedule: Prescription / Schedule D
Company: SUN PHARMACEUTICAL INDUSTRIES LIMITED
Date: 24-OCT-2022
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AC — Interleukin inhibitors (ATC, ATC/DDD)
- L04AC17 — TILDRAKIZUMAB (ATC/DDD)
